GLP-1 Agonists and Type 2 Diabetes: How They Restore Beta-Cell Function and Reverse Insulin Resistance
Type 2 diabetes used to be called a progressive, irreversible disease. Doctors told patients it would only get worse. Then GLP-1 receptor agonists arrived — and that story is changing. These drugs don't just lower blood sugar. They work at the very root of what goes wrong in type 2 diabetes: they rescue the cells that make insulin, quiet the cells that undermine them, reduce liver glucose dumping, and improve the body's ability to respond to insulin in the first place. For some patients, they're achieving something that was once considered impossible — putting type 2 diabetes into remission.
To understand why this is such a big deal, you first need to understand what type 2 diabetes actually is at the cellular level — and why it's so hard to fix.
The Root Problem: What Goes Wrong in Type 2 Diabetes
Insulin Resistance: When the Lock Stops Fitting the Key
Think of insulin as a key and your body's cells as locks. When you eat, your blood sugar rises. Insulin is released from the pancreas and travels to muscle cells, fat cells, and liver cells, where it "unlocks" glucose uptake — letting sugar into the cell to be burned for energy.
In type 2 diabetes (T2D), the locks become stiff. The key (insulin) is still there, but it no longer fits easily. This is insulin resistance: your cells stop responding normally to insulin's signal. To compensate, the pancreas pumps out more insulin. For a while, this works. Blood sugar stays normal. But the pancreas is working overtime.
Insulin resistance doesn't happen for one reason. It builds from a combination of:
- Excess visceral fat (fat around the organs) releasing inflammatory signals that disrupt insulin signaling
- Elevated free fatty acids from adipose tissue impairing insulin action in muscle and liver
- Chronic low-grade inflammation — cytokines like TNF-α and IL-6 interfere with the insulin receptor pathway
- Ectopic fat deposition — fat accumulating in the liver (hepatic steatosis) and muscle, blocking insulin's effects there
Beta-Cell Exhaustion: The Pancreas Burns Out
Your pancreas contains clusters of cells called the islets of Langerhans. Within those clusters live beta cells — the insulin factories of your body. In a healthy person, beta cells sense rising blood glucose and release exactly the right amount of insulin to bring it back down.
In T2D, beta cells are under constant attack. Years of high blood sugar (glucotoxicity) and elevated fat levels (lipotoxicity) — together called glucolipotoxicity — damage beta cells in multiple ways:
- Endoplasmic reticulum (ER) stress: Beta cells produce enormous amounts of insulin protein. When demand exceeds the cell's production capacity, misfolded proteins pile up inside the ER (the cell's protein-folding factory), triggering a stress response that eventually kills the cell.
- Oxidative stress: Beta cells are particularly vulnerable to reactive oxygen species (ROS), the byproducts of high metabolic activity. Unlike liver or muscle cells, beta cells have relatively weak antioxidant defenses.
- Apoptosis (programmed cell death): All of the above ultimately drives beta cells to self-destruct. Studies show that in established T2D, beta-cell mass can be reduced by 40–60% compared to healthy controls.
The tragic spiral: as beta cells die, less insulin is produced, blood sugar rises higher, more glucolipotoxicity occurs, more beta cells die. Traditional T2D medications largely work around this problem without addressing its root cause. GLP-1 receptor agonists actually try to reverse it.
What GLP-1 Is and Why It Matters
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. In healthy people, it does several important things: it tells the pancreas to release insulin, tells the pancreas to stop releasing glucagon (insulin's antagonist), slows the rate at which food empties from your stomach, and signals your brain that you're full.
People with type 2 diabetes have reduced GLP-1 secretion and reduced beta-cell response to GLP-1 — a double problem. GLP-1 receptor agonists (GLP-1 RAs) are drugs that mimic and amplify GLP-1's effects, staying in the body far longer than the natural hormone (which is broken down within minutes).
How GLP-1 Agonists Rescue Beta Cells
Mechanism 1: Glucose-Dependent Insulin Secretion — The Safety Lock
The single most important feature of GLP-1 RAs is how they stimulate insulin. They do it only when blood glucose is elevated. This is called glucose-dependent insulin secretion (GDIS).
Here's how it works mechanically: GLP-1 binds to its receptor on beta cells → activates adenylyl cyclase → increases cyclic AMP (cAMP) → activates protein kinase A (PKA) → enhances the activity of voltage-gated calcium channels that trigger insulin vesicle release. Crucially, this entire cascade is potentiated by glucose. When blood sugar is low, GLP-1 RAs produce little-to-no extra insulin.
This is why hypoglycemia (dangerously low blood sugar) is rare with GLP-1 RAs when used alone — a major advantage over older drugs like sulfonylureas, which push insulin secretion regardless of glucose levels.
Mechanism 2: Beta-Cell Proliferation via PDX-1
GLP-1 receptor activation doesn't just make existing beta cells work better. In animal models and cell cultures, it promotes the growth of new beta cells. The key player here is PDX-1 (pancreatic duodenal homeobox-1), a transcription factor that acts as a master regulator of beta-cell identity and insulin gene expression.
GLP-1R activation → elevated cAMP → PKA and Epac (exchange protein directly activated by cAMP) → increased PDX-1 expression → enhanced beta-cell differentiation and proliferation. GLP-1 also increases expression of MafA, another transcription factor critical to mature beta-cell function.
While the evidence in humans is harder to obtain (you can't easily biopsy human pancreatic tissue), the preclinical data consistently shows this effect, and indirect clinical data suggests improved beta-cell function with long-term GLP-1 RA use.
Mechanism 3: Protecting Beta Cells from Apoptosis
Perhaps the most medically significant effect. A 2025 meta-analysis of preclinical studies published in Frontiers in Clinical Diabetes and Healthcare found that GLP-1 RAs significantly reduced beta-cell apoptosis with a pooled mean difference of −0.10 (95% CI: −0.15 to −0.05, p = 0.0003), representing a roughly 10% reduction in apoptosis rates compared to controls.
The molecular pathway runs like this: GLP-1R → PKA → CREB (cAMP response element-binding protein) → upregulation of Bcl-2 (an anti-apoptotic protein) and downregulation of Bax (a pro-apoptotic protein). GLP-1 also activates the PI3K/Akt pathway, which promotes cell survival and suppresses caspase activation (the executioner enzymes of apoptosis).
Additionally, GLP-1 RAs reduce ER stress in beta cells by helping them manage protein folding demands — directly targeting one of the key mechanisms of glucolipotoxic damage.
Mechanism 4: Improved Insulin Gene Transcription and Biosynthesis
GLP-1 doesn't just release stored insulin — it also enhances the production of new insulin. GLP-1R signaling increases transcription of the insulin gene itself (the INS gene), as well as upregulating the enzymes involved in proinsulin processing. This means that over time, GLP-1 RAs improve the beta cell's capacity to produce insulin, not just release it.
Glucagon Suppression: Fixing the Other Half of the Problem
Most people think of T2D as "not enough insulin." But there's another hormone causing equal trouble: glucagon, produced by alpha cells in the pancreas.
Glucagon's job is to raise blood sugar when it falls too low. It does this primarily by signaling the liver to release stored glucose (glycogenolysis) and make new glucose (gluconeogenesis). In healthy people, glucagon is suppressed after meals. In type 2 diabetes, this suppression fails — alpha cells keep firing even when blood sugar is already high, telling the liver to keep pumping out glucose when the last thing anyone needs is more glucose in the blood.
This glucagon excess is a major driver of fasting hyperglycemia (high blood sugar first thing in the morning) in T2D.
GLP-1 RAs powerfully suppress glucagon secretion. Research published in Diabetes journal demonstrated that GLP-1 potentiates glucose-induced glucagon suppression in a dose-dependent manner in patients with type 2 diabetes, and that this glucagonostatic effect is preserved in T2D (unlike the insulinotropic effect, which is partially blunted). The result: the liver gets the signal to stop producing glucose it doesn't need to produce, dramatically reducing fasting blood sugar levels.
The mechanism involves GLP-1 acting on alpha cells directly (which do express GLP-1 receptors) and indirectly through stimulating somatostatin release from delta cells, which then inhibits glucagon release.
Reversing Insulin Resistance: The Weight Loss Connection
GLP-1 RAs don't directly make muscle or fat cells more insulin-sensitive in the way that metformin or thiazolidinediones do. Their primary mechanism for improving insulin resistance is weight loss — and it's highly effective.
A JCEM analysis of data from the SUSTAIN semaglutide trials found that 70–80% of the improvement in HOMA-IR (the standard clinical measure of insulin resistance) was mediated through weight loss. When you lose visceral fat:
- Adipose tissue releases fewer inflammatory cytokines (TNF-α, IL-6, resistin) that impair insulin signaling
- Free fatty acid flux to the liver decreases, reducing hepatic insulin resistance
- Ectopic fat in the liver and muscle decreases, restoring normal insulin sensitivity in those tissues
- Muscle glucose uptake (GLUT4 transporter activity) improves
In practical terms, the SUSTAIN trials showed semaglutide 1 mg reducing HOMA-IR significantly over 30–56 weeks, with the magnitude of improvement closely tracking weight loss. Tirzepatide, with its dual GIP/GLP-1 mechanism and greater weight loss, produces even more dramatic improvements in insulin sensitivity.
The Clinical Evidence: HbA1c Reduction Across Major Trials
HbA1c (glycated hemoglobin) reflects average blood sugar over 2–3 months. For reference, normal is below 5.7%, prediabetes is 5.7–6.4%, and diabetes is 6.5% and above. Most T2D patients start treatment with HbA1c in the range of 7.5–10%.
Semaglutide (STEP and SUSTAIN Trials)
- SUSTAIN-6: Semaglutide 0.5–1 mg reduced HbA1c by 1.1–1.4% vs. placebo in patients with T2D and high cardiovascular risk
- STEP-2 (obesity + T2D): Semaglutide 2.4 mg weekly reduced HbA1c by 1.6% from a mean baseline of 8.1%
- Over 50% of participants with T2D on semaglutide 2.4 mg achieved HbA1c below 6.5% — the threshold for diabetes remission
Tirzepatide (SURPASS Trials)
Tirzepatide's dual GLP-1/GIP mechanism produces markedly superior glycemic control. From the SURPASS-2 trial (the head-to-head with semaglutide 1 mg):
| Dose | HbA1c Reduction | vs. Semaglutide 1 mg |
|---|
| Tirzepatide 5 mg | −2.01% | Superior (p = 0.02) |
| Tirzepatide 10 mg | −2.24% | Superior (p < 0.001) |
| Tirzepatide 15 mg | −2.30% | Superior (p < 0.001) |
| Semaglutide 1 mg | −1.86% | Reference |
A 2025 post-hoc analysis of the SURPASS program (published in Diabetes, Obesity & Metabolism) found that participants on tirzepatide 15 mg spent significantly longer continuous time with HbA1c ≤6.5% compared to semaglutide — up to 24 weeks at target vs. 3 weeks on semaglutide. In real-world ISPOR 2025 data, tirzepatide-initiating patients with T2D showed HbA1c reductions of −1.3% versus −0.9% for semaglutide initiators.
GLP-1 vs. Traditional Diabetes Medications
| Drug Class | Primary Mechanism | Hypoglycemia Risk | Weight Effect | CV Benefit | Beta-Cell Protection |
|---|
| GLP-1 RAs | GDIS, glucagon suppression, weight loss | Very low (alone) | Weight loss (5–22%) | Yes (major trials) | Yes (anti-apoptotic) |
| Sulfonylureas | Force insulin release (glucose-independent) | High | Weight gain | Neutral/negative | Possible harm (overwork) |
| Metformin | Reduces hepatic glucose output, improves IR | Very low | Weight neutral/mild loss | Modest | Neutral |
| Insulin | Replaces insulin directly | High | Weight gain | Neutral | None |
| SGLT-2 inhibitors | Block renal glucose reabsorption | Very low | Mild weight loss | Yes (HF/renal) | None direct |
| DPP-4 inhibitors | Slow GLP-1 breakdown | Very low | Weight neutral | Neutral | Modest |
Sulfonylureas, notably, stimulate insulin release regardless of blood glucose — meaning they work even at normal or low glucose levels. This creates genuine hypoglycemia risk and potentially overworks beta cells. GLP-1 RAs' glucose-dependent mechanism makes them mechanistically safer.
The "Beta-Cell Vacation" Hypothesis
One of the most compelling ideas in type 2 diabetes medicine is that GLP-1 RAs may give exhausted beta cells a rest. Here's the logic:
In T2D, beta cells are chronically overstimulated — trying to produce more insulin to compensate for insulin resistance. This chronic overwork accelerates glucolipotoxic damage. When GLP-1 RAs reduce blood sugar through glucagon suppression, delayed gastric emptying, appetite reduction, and improved peripheral insulin sensitivity, the demand on beta cells actually decreases. They don't have to work as hard.
This "reduced beta-cell workload" combined with the direct anti-apoptotic and proliferative effects of GLP-1R signaling may allow partially damaged beta cells to recover function. Some researchers call this the "beta-cell vacation" — a period of reduced stress during which residual beta-cell function can improve.
Clinical evidence supports this. Studies measuring C-peptide (a marker of beta-cell insulin production) and mixed meal tolerance tests show improved beta-cell secretory capacity after extended GLP-1 RA treatment — suggesting genuine functional recovery, not just enhanced stimulation.
Type 2 Diabetes Remission: What the Data Shows
T2D remission is defined as HbA1c below 6.5% maintained for at least 3 months without diabetes medications. The gold standard for achieving this has historically been bariatric surgery. GLP-1 RAs are now challenging that.
In SURPASS-2, at the 15 mg tirzepatide dose, a significant proportion of participants achieved HbA1c ≤6.5%. In SURMOUNT trials, among patients with both obesity and prediabetes or newly diagnosed T2D, rates of T2D prevention and reversal were striking — tirzepatide reduced the incidence of T2D by 27% compared to semaglutide in a 2024 real-world study.
The patients most likely to achieve remission:
- Shorter diabetes duration (less beta-cell destruction has occurred)
- Higher baseline HbA1c (more room for improvement)
- Greater weight loss on GLP-1 RA therapy
- No insulin requirement at baseline (suggests residual beta-cell function)
Full remission is not guaranteed and depends heavily on residual beta-cell mass. But for newly diagnosed T2D patients caught early, GLP-1 RAs represent a genuine pathway to putting the disease into reverse.
GLP-1 + SGLT-2 Inhibitor Combination: Additive Benefits
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) — drugs like empagliflozin, dapagliflozin, canagliflozin — work through a completely different mechanism: they block the kidneys from reabsorbing glucose, causing it to be excreted in the urine. They also reduce blood pressure, reduce weight modestly, and powerfully protect the heart and kidneys.
The combination of GLP-1 RA + SGLT-2i is increasingly recognized as the gold standard dual therapy for T2D with cardiovascular risk. Multiple meta-analyses now show that combination therapy reduces MACE risk more than either drug alone. A 2025 systematic review (published in PubMed) of 18 cohort studies with 1,164,774 participants found:
- Combination therapy vs. GLP-1 RA alone: 44% lower MACE risk (RR 0.56; 95% CI 0.43–0.71)
- 50% lower all-cause mortality
- 67% lower cardiovascular mortality
- 33% lower hospitalizations for heart failure
The mechanisms are complementary: GLP-1 RAs primarily reduce atherosclerotic events and stroke; SGLT-2i primarily reduce heart failure hospitalizations and kidney disease progression. Together they cover nearly the full cardiovascular risk spectrum.
Who Benefits Most: Newly Diagnosed vs. Advanced T2D
Newly Diagnosed T2D (Duration < 5 years)
- Higher residual beta-cell mass means the anti-apoptotic and proliferative effects of GLP-1 RAs can be most impactful
- Glucagon suppression and improved insulin sensitivity can, in some cases, achieve full HbA1c normalization
- Best candidates for T2D remission
- Recommended: Consider GLP-1 RA as first-line or early add-on to metformin
Established T2D (Duration 5–15 years)
- Beta-cell mass significantly reduced but some function remains
- GLP-1 RAs provide strong HbA1c reduction, cardiovascular protection, and weight loss
- Remission less likely but metabolic improvement substantial
- Recommended: GLP-1 RA + SGLT-2i combination for those with cardiovascular risk
Advanced T2D (Duration > 15 years, on insulin)
- Beta-cell function may be severely depleted
- GLP-1 RAs still provide glucagon suppression, weight loss, and cardiovascular benefits
- May allow insulin dose reduction but rarely full discontinuation
- Recommended: GLP-1 RA added to insulin regimen; monitor for hypoglycemia (will be rare with GLP-1 alone but possible with concurrent insulin)
Frequently Asked Questions
Q: How do GLP-1 agonists lower blood sugar without causing hypoglycemia?
A: GLP-1 agonists stimulate insulin secretion only when blood glucose is elevated — a process called glucose-dependent insulin secretion (GDIS). When blood sugar is normal or low, the drug does not meaningfully increase insulin release, which is why hypoglycemia is rare when GLP-1 RAs are used without insulin or sulfonylureas. This built-in safety mechanism sets them apart from older diabetes drugs.
Q: Do GLP-1 drugs actually regenerate beta cells in humans?
A: The strongest evidence for beta-cell regeneration (proliferation) comes from animal studies and cell cultures, where GLP-1 receptor activation clearly promotes new beta-cell formation via PDX-1 transcription factor signaling. In humans, clinical data shows improved beta-cell function (measured by C-peptide and mixed meal tolerance tests) after GLP-1 RA treatment, but direct evidence of new beta-cell formation in humans is difficult to obtain. The anti-apoptotic effects — protecting existing beta cells — are supported by a 2025 meta-analysis showing a 10% reduction in apoptosis rates.
Q: Can GLP-1 agonists put type 2 diabetes into remission?
A: Yes, for some patients. Remission (HbA1c below 6.5% for 3+ months without diabetes medications) is most achievable in patients with newly diagnosed T2D, significant residual beta-cell function, and substantial weight loss on GLP-1 therapy. Tirzepatide trials show particularly high rates of achieving HbA1c ≤6.5%. Remission is less likely in patients with longstanding T2D and severely depleted beta-cell mass.
Q: How does GLP-1 suppress glucagon, and why does that matter?
A: GLP-1 binds to receptors on pancreatic alpha cells and on delta cells (which release somatostatin), reducing glucagon secretion after meals. In type 2 diabetes, glucagon is inappropriately elevated even when blood sugar is high, telling the liver to produce more glucose — making hyperglycemia worse. GLP-1 RA therapy corrects this, reducing hepatic glucose output and significantly improving fasting blood sugar levels.
Q: What is the difference between how semaglutide and tirzepatide work in type 2 diabetes?
A: Semaglutide is a pure GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. GIP has additive effects on beta-cell function, insulin secretion, and fat metabolism. In head-to-head trials (SURPASS-2), tirzepatide 15 mg reduced HbA1c by 2.30% vs. 1.86% for semaglutide 1 mg, and achieves greater and more durable glycemic control.
Q: What is HOMA-IR and how do GLP-1 agonists improve it?
A: HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated measure using fasting glucose and fasting insulin to estimate insulin resistance — higher numbers mean more resistance. GLP-1 RAs improve HOMA-IR primarily through weight loss: as visceral fat decreases, inflammatory signals that impair insulin signaling decline, and the liver and muscles become more responsive to insulin. Studies from the SUSTAIN semaglutide trials found that 70–80% of HOMA-IR improvement was mediated by weight loss.
Q: How do GLP-1 agonists compare to metformin for type 2 diabetes?
A: Metformin primarily reduces hepatic glucose production and modestly improves insulin sensitivity, with no effect on beta-cell function and no cardiovascular mortality benefit. GLP-1 RAs add glucose-dependent insulin stimulation, glucagon suppression, beta-cell protection, 5–22% weight loss, and proven cardiovascular mortality reduction. For patients with T2D and established cardiovascular disease or obesity, GLP-1 RAs are now preferred first-line or early add-on therapy per major diabetes guidelines.
Q: What is the "beta-cell vacation" hypothesis?
A: The idea that by reducing the metabolic demands on beta cells — through blood sugar lowering, glucagon suppression, and weight loss — GLP-1 RA therapy gives exhausted, partially damaged beta cells time to recover. Combined with the direct anti-apoptotic effects of GLP-1 receptor signaling, this "rest" may allow residual beta-cell function to partially normalize. Clinical evidence includes improvements in C-peptide levels and insulin secretory capacity seen with long-term GLP-1 RA treatment.
Q: Why is GLP-1 + SGLT-2 inhibitor considered the best combination for type 2 diabetes?
A: The two drug classes work through completely different mechanisms and protect different parts of the cardiovascular system. GLP-1 RAs primarily reduce atherosclerotic events (heart attacks and strokes) through anti-inflammatory, anti-atherosclerotic, and glucagon-suppressing effects. SGLT-2 inhibitors primarily reduce heart failure hospitalizations and slow kidney disease. Together they provide more comprehensive cardiorenal protection. Meta-analyses show the combination reduces MACE by ~44% more than either drug alone and cuts all-cause mortality by approximately 50%.
Q: Can people with type 1 diabetes use GLP-1 agonists?
A: GLP-1 RAs are not FDA-approved for type 1 diabetes. The glucagonostatic effect of GLP-1 is preserved in type 2 diabetes (where alpha cells retain GLP-1 receptors), but the same research shows that patients with type 1 diabetes are largely insensitive to GLP-1's glucagon-suppressive effects. Some off-label use in overweight type 1 patients occurs for weight management, but patients must understand there is no insulin-secreting benefit (as beta cells are destroyed) and the drug should not replace insulin.
Q: Do GLP-1 agonists work better in newly diagnosed or long-standing type 2 diabetes?
A: Newly diagnosed T2D patients benefit more from the beta-cell restorative effects because they retain more viable beta cells. They also have higher rates of achieving HbA1c normalization and even T2D remission. Patients with long-standing T2D still benefit substantially — from glucagon suppression, weight loss, hepatic glucose reduction, and cardiovascular protection — but full remission is less likely because significant beta-cell mass has already been permanently lost.
Key Takeaways
- Type 2 diabetes results from two parallel failures: insulin resistance (cells ignoring insulin) and beta-cell exhaustion (the insulin factory failing). GLP-1 RAs address both.
- GLP-1 agonists stimulate insulin only when blood glucose is elevated (glucose-dependent insulin secretion), making dangerous hypoglycemia rare when used without insulin or sulfonylureas.
- GLP-1 RAs protect beta cells from apoptosis through PKA → CREB → Bcl-2 upregulation, and promote beta-cell proliferation via PDX-1 transcription factor activation.
- Glucagon suppression is a critical and underappreciated mechanism — reducing inappropriate hepatic glucose output corrects fasting hyperglycemia in T2D.
- Most insulin resistance improvement (70–80%) is mediated through weight loss, which reduces visceral adiposity, systemic inflammation, and ectopic fat in liver and muscle.
- Tirzepatide (GLP-1 + GIP dual agonist) achieves HbA1c reductions of up to 2.30% — the largest of any non-insulin diabetes drug — with significantly more time at target than semaglutide.
- T2D remission is achievable for some patients, particularly those with short disease duration and substantial weight loss. This was once considered impossible with medication alone.
- The GLP-1 RA + SGLT-2 inhibitor combination represents the best evidence-based dual therapy for T2D with cardiovascular risk, cutting MACE and mortality beyond either drug alone.
- Patients with newly diagnosed T2D stand to gain the most from early GLP-1 RA initiation — preserving beta-cell function before irreversible loss.
Citations & References
-
GLP-1 receptor agonists and pancreatic beta cell apoptosis in diabetes mellitus — Frontiers in Clinical Diabetes and Healthcare (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12420244/
-
Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes — American Diabetes Association / Diabetes journal (2021): https://diabetesjournals.org/diabetes/article/70/6/1347/137707/
-
A post hoc analysis of the SURPASS clinical trial programme — Diabetes, Obesity & Metabolism (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12046485/
-
SURPASS-2: Tirzepatide vs. Semaglutide in T2D — American College of Cardiology summary (2021): https://www.acc.org/latest-in-cardiology/clinical-trials/2021/06/27/19/02/surpass-2
-
Hepato-Incretin Function of GLP-1 — Diabetes (2015): https://diabetesjournals.org/diabetes/article/64/3/715/40332/
-
Does GLP-1 suppress hepatocyte glucose production — EBioMedicine (2019): https://pmc.ncbi.nlm.nih.gov/articles/PMC6443942/
-
Reductions in Insulin Resistance are Mediated Primarily via Weight Loss with Semaglutide — Journal of Clinical Endocrinology & Metabolism (2019): https://academic.oup.com/jcem/article/104/9/4078/5423568
-
The Role of GLP-1 Receptor Agonists in Insulin Resistance — International Journal of Molecular Sciences (2022): https://pmc.ncbi.nlm.nih.gov/articles/PMC9029608/
-
Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists — PubMed (2026): https://pubmed.ncbi.nlm.nih.gov/41117973/
-
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy — Current Diabetes Reports (2026): https://pmc.ncbi.nlm.nih.gov/articles/PMC12799618/
-
GLP-1 and Cell Proliferation — Glucagon.com (molecular pathway review): https://www.glucagon.com/glp1prolif.html
-
Real-World Effectiveness of Tirzepatide vs. Semaglutide on HbA1c — ISPOR 2025: https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-1/real-world-effectiveness-of-tirzepatide-vs-semaglutide-on-hba1c-and-weight-in-glp-1-ra-na-239-ve-patients-with-t2d
-
Tirzepatide vs. Semaglutide incidence of T2D — Lancet real-world cohort (2024): https://vbn.aau.dk/ws/portalfiles/portal/742473643/Anson_et_al._2024_.pdf
